A. Lambeir

发表

Structural and mutagenesis studies of leishmania triosephosphate isomerase: a point mutation can convert a mesophilic enzyme into a superstable enzyme without losing catalytic power.

G Vriend, G. Vriend, G. Neubauer, 1999, Protein engineering.

Metal ions shape α-synuclein

A. Lambeir, A. Konijnenberg, F. Sobott, 2020, Scientific Reports.

Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties.

J. Foekens, A. Lambeir, P. Van der Veken, 2007, Journal of medicinal chemistry.

The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model

A. Lambeir, I. De Meester, M. Berg, 2021, Frontiers in Pharmacology.

A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation

L. Moons, A. Lambeir, I. De Meester, 2020, Scientific Reports.

Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post‐inflammatory rat model for irritable bowel syndrome

A. Lambeir, I. De Meester, J. Timmermans, 2018, British journal of pharmacology.

The first potent diphenyl phosphonate KLK4 inhibitors with unexpected binding kinetics

V. Magdolen, A. Lambeir, R. D. Santo, 2015 .

Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.

A. Lambeir, P. Van der Veken, J. Joossens, 2015, Journal of medicinal chemistry.

Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA).

A. Lambeir, P. Van der Veken, J. Joossens, 2012, Bioorganic & medicinal chemistry.

Modeling, mutagenesis, and structural studies on the fully conserved phosphate‐binding loop (Loop 8) of triosephosphate isomerase: Toward a new substrate specificity

Antje Rottmann, R. Abagyan, A. Rottmann, 2001, Proteins.

The importance of the conserved Arg191–Asp227 salt bridge of triosephosphate isomerase for folding, stability, and catalysis

Inari Kursula, R. Wierenga, A. Lambeir, 2002, FEBS letters.

The ionization of a buried glutamic acid is thermodynamically linked to the stability of Leishmania mexicana triose phosphate isomerase.

J. Nielsen, R. Wierenga, V. Filimonov, 2000, European journal of biochemistry.

Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV.

P. Proost, A. Lambeir, I. De Meester, 2003, Advances in experimental medicine and biology.

Kinetic study of the processing by dipeptidyl‐peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion

C. Durinx, P. Proost, A. Lambeir, 2001, FEBS letters.

Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling.

V. Fülöp, W. Luyten, A. Lambeir, 2017, European journal of medicinal chemistry.

Expression, purification and preliminary crystallographic analysis of dipeptidyl peptidase IV from Porphyromonas gingivalis.

V. Fülöp, A. Lambeir, I. De Meester, 2004, Acta crystallographica. Section D, Biological crystallography.

Inhibitor screening and enzymatic activity determination for autophagy target Atg4B using a gel electrophoresis-based assay.

A. Lambeir, M. Grootaert, G. D. De Meyer, 2016, European journal of medicinal chemistry.

Effects of Detergent on α-Synuclein Structure: A Native MS-Ion Mobility Study

A. Lambeir, F. Sobott, Stuart Maudsley, 2020, International journal of molecular sciences.

Prolyl Carboxypeptidase Mediates the C-Terminal Cleavage of (Pyr)-Apelin-13 in Human Umbilical Vein and Aortic Endothelial Cells

A. Lambeir, I. De Meester, I. Pintelon, 2021, International journal of molecular sciences.

Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP).

Ruth Geiss-Friedlander, A. Lambeir, I. De Meester, 2019, ACS medicinal chemistry letters.

Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.

A. Lambeir, I. De Meester, L. Maes, 2013, ACS medicinal chemistry letters.

DPP8/DPP9 inhibition elicits canonical Nlrp1b inflammasome hallmarks in murine macrophages

Ruth Geiss-Friedlander, A. Lambeir, I. De Meester, 2019, Life Science Alliance.

The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis

A. Lambeir, I. De Meester, L. Baerts, 2015, Front. Immunol..

Synthesis and evaluation of azaproline peptides as potential inhibitors of dipeptidyl peptidase IV and prolyl oligopeptidase

A. Lambeir, A. Haemers, K. Augustyns, 1995, Letters in Peptide Science.

Development of potent and selective dipeptidyl peptidase II inhibitors.

A. Lambeir, B. Bauvois, I. De Meester, 2002, Bioorganic & Medicinal Chemistry Letters.

ECM1 interacts with fibulin-3 and the beta 3 chain of laminin 332 through its serum albumin subdomain-like 2 domain.

A. Lambeir, J. Merregaert, A. El Ghalbzouri, 2009, Matrix biology : journal of the International Society for Matrix Biology.

Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form.

A. Lambeir, I. De Meester, J. Ketelslegers, 2006, Clinical chemistry.

Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis

J. Aernouts, A. Lambeir, P. Van der Veken, 2017, Thrombosis and Haemostasis.

Translational research on prolyl oligopeptidase inhibitors: the long road ahead

A. Lambeir, 2011, Expert opinion on therapeutic patents.

The formation and decay of the oxyferrous forms of the cytochromes P-450 isolated from Rhizobium japonicum. Rapid spectral scan and stopped flow studies

A. Lambeir, H. Dunford, C. Appleby, 1985 .

Prolyl carboxypeptidase activity in the circulation and its correlation with body weight and adipose tissue in lean and obese subjects

H. Noels, P. Venge, A. Lambeir, 2018, PloS one.

Validation of a specific prolylcarboxypeptidase activity assay and its suitability for plasma and serum measurements.

A. Lambeir, I. De Meester, P. Van der Veken, 2013, Analytical biochemistry.

Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke

J. Michel, J. Desilles, M. Mazighi, 2020, Journal of thrombosis and haemostasis : JTH.

A fluorescence stopped flow study of colchicine binding to tubulin.

A. Lambeir, Y. Engelborghs, 1981, The Journal of biological chemistry.

The expression of proline-specific enzymes in the human lung.

D. Adriaensen, A. Lambeir, I. De Meester, 2017, Annals of translational medicine.

Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).

A. Lambeir, I. De Meester, L. Maes, 2014, Journal of medicinal chemistry.

Prolyl endopeptidase is involved in the degradation of neural cell adhesion molecules in vitro

M. Morawski, A. Lambeir, R. Van Elzen, 2016, Journal of Cell Science.

The role of the S1 binding site of carboxypeptidase M in substrate specificity and turn-over.

A. Lambeir, K. Gilany, G. Surpateanu, 2007, Biochimica et biophysica acta.

Proteolytic Cleavage of Bioactive Peptides and Protease-Activated Receptors in Acute and Post-Colitis

P. Hulpiau, H. Koistinen, U. Stenman, 2021, International journal of molecular sciences.

Efforts towards an on-target version of the Groebke-Blackburn-Bienaymé (GBB) reaction for discovery of druglike urokinase (uPA) inhibitors.

A. Lambeir, Dries Van Rompaey, P. Van der Veken, 2019, Chemistry.

In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma.

A. Lambeir, I. De Meester, P. Budde, 2009, Biochemical pharmacology.

Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis

A. Lambeir, J. Mertens, D. Hendriks, 2019, Journal of thrombosis and haemostasis : JTH.

Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction

A. Lambeir, J. Bosmans, P. Veken, 2015, Journal of thrombosis and haemostasis : JTH.

Presence and release of SR-17 (chromogranin B586–602) in the porcine splenic nerve and its enzymatic degradation by CD26/dipeptidyl peptidase IV

C. Durinx, A. Lambeir, S. Scharpe, 2002, Regulatory Peptides.

A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro.

P. Proost, A. Lambeir, I. De Meester, 2002, Biochemical pharmacology.

Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside

A. Lambeir, I. De Meester, J. Bartunek, 2009, Clinical chemistry and laboratory medicine.

Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 1: Substitution of the glycine carboxylic acid group.

A. Fairlamb, A. Lambeir, A. Yamani, 2002, Bioorganic & medicinal chemistry letters.

Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases.

A. Lambeir, I. De Meester, P. Van der Veken, 2005, Journal of medicinal chemistry.

Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?

Xin Chen, A. Lambeir, I. De Meester, 2011, Journal of medicinal chemistry.

DPP4 inhibitors for diabetes--what next?

A. Lambeir, I. De Meester, S. Scharpe, 2008, Biochemical pharmacology.

The potential of carboxypeptidase M as a therapeutic target in cancer

A. Lambeir, Catherine J Denis, 2013, Expert opinion on therapeutic targets.

Regulation of intestinal permeability: The role of proteases

A. Lambeir, I. De Meester, B. D. De Winter, 2017, World journal of gastroenterology.

On the mechanism of chlorination by chloroperoxidase.

A. Lambeir, M. Kashem, M. Pickard, 1987, Archives of biochemistry and biophysics.

Importance of biofilm formation and dipeptidyl peptidase IV for the pathogenicity of clinical Porphyromonas gingivalis isolates.

W. Teughels, M. Quirynen, A. Lambeir, 2014, Pathogens and disease.

Vibrational Circular Dichroism Sheds New Light on the Competitive Effects of Crowding and β-Synuclein on the Fibrillation Process of α-Synuclein.

T. Keiderling, A. Lambeir, P. Baatsen, 2018, Biochemistry.

Truncation of Macrophage-derived Chemokine by CD26/ Dipeptidyl-Peptidase IV beyond Its Predicted Cleavage Site Affects Chemotactic Activity and CC Chemokine Receptor 4 Interaction*

P. Allavena, G. Opdenakker, P. Proost, 1999, The Journal of Biological Chemistry.

Small molecule 3PO inhibits glycolysis but does not bind to 6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase‐3 (PFKFB3)

A. Lambeir, G. D. De Meyer, W. Martinet, 2020, FEBS letters.

Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).

Xin Chen, A. Lambeir, I. De Meester, 2005, Biochemical pharmacology.

Kinetics of the reaction of compound II of horseradish peroxidase with hydrogen peroxide to form compound III.

A. Lambeir, S. A. Adediran, S. Adediran, 1989, European journal of biochemistry.

Carboxypeptidase M Expressed by Human Bone Marrow Cells Cleaves the C‐Terminal Lysine of Stromal Cell‐Derived Factor‐1α: Another Player in Hematopoietic Stem/Progenitor Cell Mobilization?

A. Lambeir, A. Jalili, L. Marquez-Curtis, 2008, Stem cells.

Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold

A. Lambeir, J. Joossens, K. Augustyns, 2014 .

Glyceraldehyde-phosphate dehydrogenase from Trypanosoma brucei. Comparison of the glycosomal and cytosolic isoenzymes.

F. Opperdoes, J. V. Van Beeumen, A. Lambeir, 1987, European journal of biochemistry.

The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.

C. Durinx, A. Lambeir, A. Haemers, 1999, Current medicinal chemistry.

Dipeptidyl Peptidase IV (DPPIV/CD26)‐Based Prodrugs of Hydroxy‐Containing Drugs

A. Lambeir, J. Balzarini, M. Camarasa, 2012, ChemMedChem.

Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors.

Xin Chen, A. Lambeir, I. De Meester, 2008, Bioorganic & medicinal chemistry letters.

Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.

Xin Chen, A. Lambeir, I. De Meester, 2008, Bioorganic & medicinal chemistry letters.

Dipeptidyl peptidase 8/9‐like activity in human leukocytes

Xin Chen, A. Lambeir, I. De Meester, 2007, Journal of leukocyte biology.

Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets

A. Lambeir, I. De Meester, S. Scharpe, 2009, Clinical chemistry and laboratory medicine.

C-Terminal Clipping of Chemokine CCL1/I-309 Enhances CCR8-Mediated Intracellular Calcium Release and Anti-Apoptotic Activity

J. Renauld, P. Proost, A. Lambeir, 2012, PloS one.

The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma.

A. Lambeir, I. De Meester, R. Van Elzen, 2019, Clinica chimica acta; international journal of clinical chemistry.

Spectral properties of the higher oxidation states of prostaglandin H synthase.

L. Marnett, A. Lambeir, H. Dunford, 1985, Advances in prostaglandin, thromboxane, and leukotriene research.

Dysregulation of the renin-angiotensin system during lung ischemia-reperfusion injury

P. V. Van Schil, A. Lambeir, I. De Meester, 2016, Experimental lung research.

Design, synthesis, and SAR of potent and selective dipeptide-derived inhibitors for dipeptidyl peptidases.

A. Lambeir, I. De Meester, P. Van der Veken, 2003, Journal of medicinal chemistry.

Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin‐activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models

J. Michel, A. Lambeir, J. Mertens, 2018, Journal of thrombosis and haemostasis : JTH.

A. Lambeir, S. Scharpe, I. Brandt, 2007, Clinica chimica acta; international journal of clinical chemistry.

The reaction between NADPH and mercuric reductase from Pseudomonas aeruginosa.

A. Lambeir, S. Lindskog, L. Sahlman, 1984, The Journal of biological chemistry.

Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases

A. Lambeir, I. De Meester, B. D. De Winter, 2016, World journal of gastroenterology.

The adaptability of the active site of trypanosomal triosephosphate isomerase as observed in the crystal structures of three different complexes

M. Noble, F. Opperdoes, W. Hol, 1991, Proteins.

A rapid-scan spectrometric and stopped-flow study of compound I and compound II of Pseudomonas cytochrome c peroxidase.

A. Lambeir, H. Dunford, N. Ellfolk, 1985, Archives of biochemistry and biophysics.

Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator.

A. Lambeir, P. Van der Veken, J. Joossens, 2004, Journal of medicinal chemistry.

Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors.

A. Lambeir, I. De Meester, A. Haemers, 1999, Journal of medicinal chemistry.

Rapid parallel synthesis of dipeptide diphenyl phosphonate esters as inhibitors of dipeptidyl peptidases.

A. Lambeir, I. De Meester, P. Van der Veken, 2003, Journal of combinatorial chemistry.

Enzyme Activity and Immunohistochemical Localization of Dipeptidyl Peptidase 8 and 9 in Male Reproductive Tissues

Xin Chen, A. Lambeir, V. Dubois, 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Rapid parallel synthesis of dipeptide diphenyl phosphonate esters as inhibitors of dipeptidyl peptidases.

A. Lambeir, I. De Meester, P. Van der Veken, 2003, Journal of combinatorial chemistry.

Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates.

Xin Chen, A. Lambeir, I. De Meester, 2007, Journal of medicinal chemistry.

Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.

Georgiana Surpateanu, Jurgen Joossens, Koen Augustyns, 2006, Journal of medicinal chemistry.

In vivo effects of a potent, selective DPPII inhibitor: UAMC00039 is a possible tool for the elucidation of the physiological function of DPPII.

A. Lambeir, I. De Meester, P. Van der Veken, 2006, Advances in experimental medicine and biology.

Kinetics of the oxidation of ascorbic acid, ferrocyanide and p-phenolsulfonic acid by chloroperoxidase compounds I and II.

A. Lambeir, M. Pickard, H. Dunford, 1987, European journal of biochemistry.

Dipeptide-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl peptidase IV.

A. Lambeir, I. De Meester, A. Haemers, 1996, Biochimica et Biophysica Acta.

High-pressure effect on the equilibrium and kinetics of cyanide binding to chloroperoxidase.

A. Lambeir, K. Heremans, H. Dunford, 1983, Biophysical chemistry.

Rapid-scan stopped-flow studies of the pH dependence of the reaction between mercuric reductase and NADPH.

A. Lambeir, S. Lindskog, L. Sahlman, 1986, European journal of biochemistry.

Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors.

A. Lambeir, I. De Meester, V. Matheeussen, 2012, Clinica chimica acta; international journal of clinical chemistry.

Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV

C. Durinx, A. Lambeir, I. De Meester, 2003, Critical reviews in clinical laboratory sciences.

A kinetic and spectral study of the alkaline transitions of chloroperoxidase.

A. Lambeir, H. Dunford, 1983, Archives of biochemistry and biophysics.

Substrate Activity Screening (SAS) and Related Approaches in Medicinal Chemistry

A. Lambeir, J. Joossens, K. Augustyns, 2016, ChemMedChem.

Oxygen binding to dithionite-reduced chloroperoxidase.

A. Lambeir, H. Dunford, 1985, European journal of biochemistry.

Kinetics of cyanide binding to chloroperoxidase in the presence of nitrate: detection of the influence of a heme-linked acid group by shift in the appa

A. Lambeir, M. Pickard, H. Dunford, 1983 .

The dipeptidyl peptidase IV (CD26, EC 3.4.14.5) inhibitor vildagliptin is a potent antihyperalgesic in rats by promoting endomorphin-2 generation in the spinal cord.

W. Luyten, A. Lambeir, J. Szalai, 2011, European journal of pharmacology.

Efficient conversion of tetrapeptide-based TSAO prodrugs to the parent drug by dipeptidyl-peptidase IV (DPPIV/CD26).

A. Lambeir, J. Balzarini, M. Camarasa, 2007, Antiviral Research.

Carboxypeptidase M: Multiple alliances and unknown partners.

A. Lambeir, S. Scharpe, D. Hendriks, 2009, Clinica chimica acta; international journal of clinical chemistry.

A steady state kinetic analysis of the reaction of chloroperoxidase with peracetic acid, chloride, and 2-chlorodimedone.

A. Lambeir, H. Dunford, 1983, The Journal of biological chemistry.

The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.

Erik A. A. Wallén, A. Urtti, A. Lambeir, 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Search for substrates for prolyl oligopeptidase in porcine brain

B. Devreese, J. Beeumen, A. Lambeir, 2005, Peptides.

Spatiotemporal expression and inhibition of prolyl oligopeptidase contradict its involvement in key pathologic mechanisms of kainic acid–induced temporal lobe epilepsy in rats

S. Dedeurwaerdere, A. Lambeir, R. Van Elzen, 2018, Epilepsia open.

Mapping of Carboxypeptidase M in Normal Human Kidney and Renal Cell Carcinoma

A. Lambeir, E. Fransen, M. Kockx, 2013, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Carboxypeptidase M in apoptosis, adipogenesis and cancer.

P. Proost, A. Lambeir, D. Hendriks, 2013, Clinica chimica acta; international journal of clinical chemistry.

Glucosephosphate isomerase from Trypanosoma brucei. Cloning and characterization of the gene and analysis of the enzyme.

F. Opperdoes, J. V. Van Beeumen, R. Wierenga, 1989, European journal of biochemistry.

Dipeptidyl peptidase 9 (DPP9) from bovine testes: identification and characterization as the short form by mass spectrometry.

Y. Guisez, A. Lambeir, I. De Meester, 2010, Biochimica et biophysica acta.

Chemically diverse activity-based probes with unexpected inhibitory mechanisms targeting trypsin-like serine proteases

G. Boeckxstaens, A. Lambeir, I. De Meester, 2023, Frontiers in Chemistry.

Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.

A. Lambeir, I. De Meester, P. Van der Veken, 2012, Bioorganic & medicinal chemistry letters.

Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.

M. Parmentier, C. Durinx, G. Opdenakker, 2001, Blood.

Carboxylate isosteres for caspase inhibitors: the acylsulfonamide case revisited.

A. Lambeir, M. Lamkanfi, L. Vande Walle, 2017, Organic & biomolecular chemistry.

Dipeptidyl peptidase II and leukocyte cell death.

A. Lambeir, I. De Meester, D. Schrijvers, 2006, Biochemical pharmacology.

Kinetic Investigation of Chemokine Truncation by CD26/Dipeptidyl Peptidase IV Reveals a Striking Selectivity within the Chemokine Family*

C. Durinx, P. Proost, A. Lambeir, 2001, The Journal of Biological Chemistry.

In situ prolyl oligopeptidase activity assay in neural cell cultures

A. Lambeir, M. Gérard, P. Veken, 2012, Journal of Neuroscience Methods.

Peptide substrates of dipeptidyl peptidases.

A. Lambeir, I. De Meester, S. Scharpe, 2006, Advances in experimental medicine and biology.

Characterisation of a Novel Series of Aprotinin-Derived Anticoagulants

J. Vermylen, J. Sixma, A. Lambeir, 1995, Thrombosis and Haemostasis.

Strategies in the Design of Inhibitors of Serine Proteases of the Coagulation Cascade - Factor Xa

I. Lasters, S. Tamura, P. Stanssens, 1995, European Journal of Medicinal Chemistry.

Structure and function relationship in prolyl oligopeptidase.

A. Lambeir, R. Van Elzen, 2011, CNS & neurological disorders drug targets.

Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2)

P. Jorens, A. Lambeir, I. De Meester, 2020, PloS one.

Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7).

A. Lambeir, I. De Meester, B. Leiting, 2005, The Biochemical journal.

Prolyl carboxypeptidase purified from human placenta: its characterization and identification as an apelin-cleaving enzyme.

A. Lambeir, I. De Meester, R. Van Elzen, 2016, Biochimica et biophysica acta.

A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma.

J. V. Van Beeumen, B. Devreese, A. Lambeir, 1997, Biochimica et biophysica acta.

Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV

A. Haemers, Koen Augustyns, G. Vanhoof, 1997 .

The catalytic cycle of biosynthetic thiolase: a conformational journey of an acetyl group through four binding modes and two oxyanion holes.

Petri Kursula, R. Wierenga, A. Lambeir, 2002, Biochemistry.

CPM (carboxypeptidase M)

A. Lambeir, 2014 .

Atlas of Genetics and Cytogenetics in Oncology and Haematology CPM ( carboxypeptidase M )

A. Lambeir, 2022 .

A quantitative description of microtubule formation in the presence of tubulin-colchicine.

A. Lambeir, Y. Engelborghs, 1983, European journal of biochemistry.

Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV

Dominique Schols, Paul Proost, E. De Clercq, 1998, The Journal of Biological Chemistry.

Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 2: substitution of the glycine part.

A. Fairlamb, A. Lambeir, A. Yamani, 2002, Bioorganic & medicinal chemistry letters.

Preliminary crystallographic studies of glycosomal glyceraldehyde phosphate dehydrogenase from Trypanosoma brucei brucei.

R J Read, F. Opperdoes, R. Read, 1987, Journal of molecular biology.

Repositioning the Substrate Activity Screening (SAS) Approach as a Fragment‐Based Method for Identification of Weak Binders

Rafaela Gladysz, Matthias Cleenewerck, Jurgen Joossens, 2014, Chembiochem : a European journal of chemical biology.

Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood–brain barrier dysfunction

A. Lambeir, R. Brouns, M. Ieven, 2018, Journal of thrombosis and haemostasis : JTH.

P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy.

V. Fülöp, V. Baekelandt, A. Lambeir, 2012, Journal of medicinal chemistry.

Prolyl oligopeptidase stimulates the aggregation of α-synuclein

V. Baekelandt, B. Devreese, A. Lambeir, 2008, Peptides.

The effect of prolyl oligopeptidase inhibition on extracellular acetylcholine and dopamine levels in the rat striatum

J. Hakkarainen, A. Lambeir, M. Forsberg, 2012, Neurochemistry International.

Corrigendum to: Kinetic study of the processing by dipeptidyl‐peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion (FEBS 25376)

C. Durinx, P. Proost, A. Lambeir, 2002 .

Rapid spectral scan and stopped-flow studies of carbon monoxide binding to bovine adrenocortical cytochrome P-450scc.

A. Lambeir, M. Kashem, H. Dunford, 1987, Biochimica et Biophysica Acta.

Isolation and identification of naturally modified C-C chemokines MCP-1, MCP-2 and RANTES: effects of posttranslational modifications on receptor usage, chemotactic and anti-HIV-1 activity.

E. De Clercq, P. Proost, A. Lambeir, 1998, European Cytokine Network.

Exploration of the active site of dipeptidyl peptidase IV from Porphyromonas gingivalis. Comparison with the human enzyme.

V. Fülöp, A. Lambeir, I. De Meester, 2003, Advances in experimental medicine and biology.

A new synthetic method for proline diphenyl phosphonates

A. Lambeir, A. Haemers, K. Augustyns, 1995 .

Structural determinants for ligand binding and catalysis of triosephosphate isomerase.

R. Wierenga, A. Lambeir, I. Kursula, 2001, European journal of biochemistry.

Prolylisoxazoles: potent inhibitors of prolyloligopeptidase with antitrypanosomal activity.

S. Croft, A. Lambeir, P. Van der Veken, 2003, Bioorganic & medicinal chemistry letters.

Purification and characterization of a dipeptidyl peptidase 9-like enzyme from bovine testes

Xin Chen, A. Lambeir, J. Creemers, 2007 .

In Vitro and In Situ Activity-Based Labeling of Fibroblast Activation Protein with UAMC1110-Derived Probes

O. De Wever, A. Lambeir, I. De Meester, 2021, Frontiers in Chemistry.

Dynamics and ligand-induced conformational changes in human prolyl oligopeptidase analyzed by hydrogen/deuterium exchange mass spectrometry

A. Lambeir, A. Economou, P. Veken, 2017, Scientific Reports.

Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides.

E. Bosmans, C. Durinx, A. Lambeir, 2000, European journal of biochemistry.

Interaction of prolyl oligopeptidase with α-synuclein.

A. Lambeir, 2011, CNS & neurological disorders drug targets.

Probing for improved selectivity with dipeptide-derived inhibitors of dipeptidyl peptidases 8 and 9: the impact of P1-variation

Xin Chen, A. Lambeir, J. Joossens, 2016 .

Functional role of the conserved active site proline of triosephosphate isomerase.

P. Neubauer, R. Wierenga, A. Lambeir, 2007, Biochemistry.

Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).

A. Lambeir, I. De Meester, L. Maes, 2014, Journal of medicinal chemistry.

The expression of proline-specific enzymes in the human lung.

D. Adriaensen, A. Lambeir, I. De Meester, 2017, Annals of translational medicine.

Purification and characterization of dipeptidyl peptidase IV-like enzymes from bovine testes.

Xin Chen, A. Lambeir, I. De Meester, 2008, Frontiers in bioscience : a journal and virtual library.

The Noradrenergic Neuron, a Multipeptide Secretory Cell

C. Durinx, A. Lambeir, W. Potter, 2002 .

Demonstration of glycosomes (microbodies) in the Bodonid flagellate Trypanoplasma borelli (Protozoa, Kinetoplastida).

F. Opperdoes, E. Schaftingen, A. Lambeir, 1988, Molecular and biochemical parasitology.

Protein engineering of xylose (glucose) isomerase from Actinoplanes missouriensis. 1. Crystallography and site-directed mutagenesis of metal binding sites.

J. Janin, J. Jenkins, S. Wodak, 1993, Biochemistry.

Protein engineering of xylose (glucose) isomerase from Actinoplanes missouriensis. 3. Changing metal specificity and the pH profile by site-directed mutagenesis.

J. Janin, J. Jenkins, S. Wodak, 1992, Biochemistry.

Spatiotemporal expression and inhibition of prolyl oligopeptidase contradict its involvement in key pathologic mechanisms of kainic acid–induced temporal lobe epilepsy in rats

S. Dedeurwaerdere, A. Lambeir, R. Van Elzen, 2018, Epilepsia open.

Kinetic properties of triose-phosphate isomerase from Trypanosoma brucei brucei. A comparison with the rabbit muscle and yeast enzymes.

F. Opperdoes, R. Wierenga, A. Lambeir, 1987, European journal of biochemistry.

The adaptability of the active site of trypanosomal triosephosphate isomerase as observed in the crystal structures of three different complexes

M. Noble, F. Opperdoes, W. Hol, 1991, Proteins.

The effects of CD26/DPP IV-targeted therapy on acute allograft rejection.

A. Lambeir, J. Kupiec-Weglinski, I. De Meester, 1997, Transplantation proceedings.

In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (Prodipine).

A. Lambeir, I. De Meester, G. D. De Meyer, 1997, Biochemical pharmacology.

A prolyl oligopeptidase inhibitor, KYP‐2047, reduces α‐synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease

V. Baekelandt, A. Lambeir, R. Van Elzen, 2012, British journal of pharmacology.